The Economist profiles Plasmodium vivax, a type of malaria that affects between 80 million to 390 million people worldwide annually with a cost to sufferers between $1.4 billion and $4 billion each year. However, compared with the related Plasmodium falciparum parasite, vivax rarely kills and therefore falls lower on the list of global health funding priorities, according to the magazine, which also presents a video titled, “Malaria’s frontlines” (5/26).